Table of Contents Table of Contents
Previous Page  43 / 916 Next Page
Show Menu
Previous Page 43 / 916 Next Page
Page Background

25th European Congress of Psychiatry / European Psychiatry 41S (2017) S8–S52


cal & public health concern: The European Union’s CAMHEE report

recommends better information on CAPRI risks and resilience and

to enable interventions to target the highest risk. This is important

because although large numbers of children are in the riskset, most

remain resilient. Research needs to support delivery of the CAMHEE

initiative by understanding who is at risk and how we can target

them early before their life trajectories are fatally disrupted.

To do this, we aimto create groundbreaking cross- national datasets

providing robust data on CAPRI prevalence & life trajectories

needed to plan future services.

But epidemiology alone cannot expose how risk creates effects at

the individual level. We need to know which CAPRI to target with

potentially expensive, time-consuming specialist services

Powerful neuroscience techniques such as functional near infrared

spectroscopy are now available with which we can link epidemio-

logical risk to elucidate effects of exposure within individual infant

brain. This unique interdisciplinary approach yokes robust epi-

demiological evidence to cutting-edge optical imaging that can be

undertaken in very young infants.

This allows us to target developments in clinical interventions for

CAPRI to those in greatest need and potentially to those most

vulnerable with the future aim to identify early biomarkers of

abnormality for targeting intervention in CAPRI.

Disclosure of interest

The author declares that he has no compet-

ing interest.

Symposium: diagnostic tools and medical device

technologies in psychiatry


Big data market analysis of e-health in

medical neuroscience

A. Stellbrink

, E. M


Kliniken der Heinrich-Heine-universität Düsseldorf, klinik und

poliklinik für psychiatrie und psychotherapie, Düsseldorf, Germany

Corresponding author.

Depression is associated with more than 100,000 patent applica-

tions for its diagnosis and prognosis, the highest number among

mental disorders. This is followed by schizophrenia with 47,000,

bipolar disorder with 32,110 and hypomania with 11,377. Among

diagnostic tools, magnetic resonance imaging is associated with

more than 31,000 patent applications. Among recent technologies,

biomarkers are associated with more than 12,000 epigenetics with

about 970 metabolomics with 515 genome-wide association study

(GWAS) with 486 and bionics with 497 patent applications. The

patent applications related to diagnosis and prognosis of psychi-

atric diseases peaked in 2008 andwas overall decreasing until 2016,

with a local peak in 2013. This trend has been observed despite

the value addition of recent technologies like machine learning, big

data and internet of things. However, more conservative diagnostic

tools from the last decade like magnetic resonance imaging, epige-

netics, bionics and neuro-psychological testing are improved by the

recent technologies. For example, bionics is improved by sensors of

internet of things to collect the data frompatients around theworld

and use the big data analytics to efficiently diagnose the psychiatric

diseases. The Regents of the University of California and Human

Genome Sciences Incorporation are the respective academic and

non-academic institutions leading the innovations related to diag-

nosis and prognosis of psychiatric diseases.

Disclosure of interest

The authors declare that they have no com-

peting interest.


The ethics of mobile health


S. Galderisi

, F. Caputo

University of Campania “Luigi Vanvitelli”, department of psychiatry,

Naples, Italy

Corresponding author.


Mobile health (m-health) technology has been

growing rapidly in the last decades. The use of this technology

represents an advantage, especially for reaching patients who oth-

erwise would have no access to healthcare. However, many ethical

issues arise from the use of m-health. Health equity, privacy poli-

cies, adequate informed consent and a competent, safe and high

quality healthcare need to be guaranteed; professional standards

and quality of doctor-patient relationship in the digital setting

should not be lower than those set for in-person practice.


To assess advantages and threats that may arise from the

wide use of m-health technologies, in order to guarantee the appli-

cation of the best medical practices, resulting in the highest quality



A literature search has been conducted to highlight the

most pressing ethical issues emerging from the spreading of m-

health technologies.


Fewethical guidelines on the appropriate use ofm-health

have been developed to help clinicians adopt a professional con-

duct within digital settings. They focus on the need for professional

associations to define ethical guidelines and for physicians to take

care of their education and online behavior when using m-health



The rapid spreading of m-health technologies urges

us to evaluate all ethical issues related to its use. It would be

advisable to produce an ethical code for the use of these new

technologies, to guarantee health equity, privacy protection, high

quality doctor-patient relationships and to ensure that m-health is

not chosen over traditional care for merely economic purposes.

Disclosure of interest

SG received honoraria or Advisory

board/consulting fees from the following companies: Lund-

beck, Janssen Pharmaceuticals, Hoffman-La Roche, Angelini-Acraf,

Otsuka, Pierre Fabre and Gedeon-Richter. All other authors have


Symposium: Social cognition in schizophrenia:

pathophysiology, functional implications and

treatment options


Disorganization and social cognition:

Data from the italian network of

research on psychoses

P. Rocca

Unito, Italy

Social cognition (SC) refers broadly to the domains of cognitive

functions that are employed in socially relevant situations. These

disturbances have been found to be strongly related to disor-

ganized and negative symptoms in schizophrenia. Each of the

disorganization symptoms suggests a diminishment or absence

of organization. There seems to be a loss of the ability to be

directed toward or committed to a particular focal topic or goal.

Such conditions are likely to impact patients’ drives or motiva-

tions to initiate goal-directed activities that could yield pleasurable

opportunities. Moreover, it has been suggested that disorganized